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soriasis has both cutaneous and systemic
manifestations. Psoriatic pathogenesis is
driven by chronic, immune-mediated inflam-
mation.1,2 Multiple cormorbidities of psoriasis, such
as obesity, diabetes, hypertension, and dyslipidemia
predispose to cardiovascular disease. Furthermore,
psoriasis alone may represent an independent
cardiovascular risk factor.3
Biologic therapies specifically targeting inflam-
matory pathways have emerged in the management
of psoriasis. Given the role of chronic inflammation
in both psoriasis and cardiovascular disease, the
impact of these therapeutic agents on cardiovascular
risk has been of research interest. To date, the data
suggest an overall reduction in risk for cardiovascu-
lar events with tumor necrosis factorealpha inhibi-
tors and a neutral effect for ustekinumab, an IL-12/23
inhibitor.1,4,5 Fewer data exist to corroborate the
relationship between ustekinumab and cardiovascu-
lar risk, and concern still exists for an increased
susceptibility to major adverse cardiovascular
events.1,6-8 There are limited data guiding the
combination of biologic agents in the management
of psoriasis and psoriatic arthritis.CASE REPORT
We present a 62-year-old man with the metabolic
syndrome: obesity (body mass index, 47), type 2
diabetes mellitus, hypertension, and hypercholester-
olemia and a 15-year history of severe plaque
psoriasis and psoriatic arthritis involving thethe Dermatology Department, University of Connecticut
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respond to several prior treatments including topical
corticosteroids, narrow-band ultraviolet B photo-
therapy, cyclosporine, infliximab, and adalimumab.
He began taking etanercept, 50 mg once weekly,
combined with methotrexate administered as a
25-mg subcutaneous weekly dose. Significant
clearance of psoriasis and the diminution of arthritis
ensued. However, lack of affordability necessitated a
switch from subcutaneous to oral methotrexate
taken at 20 mg weekly. This formulation change
resulted in increased gastrointestinal intolerability
and a significant return of psoriasis. He was
instructed to discontinue use of both etanercept
and oral methotrexate, and ustekinumab, 90 mg,
was administered subcutaneously at weeks 0 and 4.
The psoriasis rapidly cleared, yet the arthritic and
enthesopathic symptoms returned. Unbeknownst to
the treating practitioner, the patient restarted etaner-
cept, 50 mg weekly, for approximately 4 weeks
before his next office visit. At that visit, the patient
displayed completely clear skin and had no symp-
toms of psoriatic arthritis. The patient stated that he
never felt better and insisted on maintaining the 2-
biologic regimen, which was guardedly permitted by
the physician and covered by his insurance plan.
Approximately 5 months after initiation of the
combined regimen, the patient experienced unstable
angina. The patient had no previous history of
coronary artery disease but had several risk factors
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4 Babalola, Lakdawala, and Stroberhistory of cardiovascular disease. He underwent
percutaneous coronary intervention with placement
of drug-eluting stents. Additionally, dual antiplatelet
pharmacologic therapy with clopidogrel and aspirin
was initiated. For management of his comorbidities,
he maintained an antihypertensive regimen, atorvas-
tatin for dyslipidemia and insulin and metformin for
glycemic control. At a 1-month follow-up visit, he
remained free of angina, and both the psoriasis and
psoriatic arthritis remained under good control with
the continuation of concomitant etanercept and
ustekinumab.DISCUSSION
This patient, receiving concomitant treatment with
ustekinumab and etanercept, experienced a great
reduction in both the signs and symptoms of psoriatic
disease. In this case, ustekinumab effectively cleared
the psoriasis, whereas etanercept treated the symp-
toms of psoriatic arthritis. A solitary case report does
not represent enough data to advocate the routine
use of combination biologic regimens. However, a
customized approach to the management of psoriasis
always is necessary. This patient, who did not respond
to multiple other approaches, experienced dramatic
improvement in disease control with the combined
regimen. However, he experienced a cardiovascular
event that cannot be definitively attributed to the
therapies. It remains unclear whether biologic
therapy, particularly ustekinumab, which was new
to the patient and temporally associated, or the
combination of ustekinumab and etanercept played
an exacerbating role in the cardiovascular adverse
event or whether the angina represented an unrelated
consequence of the longstanding metabolic
syndrome. Regardless, he is receiving antiplatelet
therapy and pharmacologic therapy for hypertension,
dyslipidemia, and diabetes to help prevent futurecardiovascular sequelae. Although both biologic
agents were covered by the patient’s health insurance,
issues related to cost effectiveness obviously make
this approach to therapy impractical for most. In this
instance, after an extensive discussion of the potential
risks and benefits, both the patient and the treating
physician have opted for the continuation of the
combined biologic therapy. Close monitoring of the
patient will ensue.
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